Genmab — November 2020
-
God morgen efter en overraskende valgnat.
-
-
Aktier/tendens: Vestas slår konsensus på valg- og regnskabstung daghttps://www.proinvestor.com/investornyt
-
Bliver Q3 i dag et non event eller er der noget vi skal bide mærke i inden CMD?
-
Flot stigning og der er blot omsat ca. 24.000 aktier. Købssiden er meget insisterende
-
Temmelig vild dag.
-
-
The most advanced candidate in the portfolio is REGN1979, a CD20/CD3-targeting antibody that made a bit of a splash last year with preliminary human data in non-Hodgkin’s lymphoma (NHL). Regeneron also has a BCMA/CD3 agent that is expected to generate initial efficacy results in multiple myeloma (MM), and a handful of even earlier stage candidates in Phase I testing.
-
Analytiker øjner opjustering fra Genmab
Der kan være en opjustering på vej fra medicinalselskabet Genmab, der onsdag fremlægger sine tal for tredje kvartal, vurderer Sydbank på baggrund af tal fra partneren Johnson & Johnson, som allerede for mere end 14 dage siden løftede sløret for et bedre end ventet salg af kræftmidlet Darzalex.
(medwatch.dk)
-
Updated Phase 1 Results of Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Relapsed and/or Refractory Multiple Myeloma (RRMM) https://ashpublications.org/blood/article/136/Supplement 1/27/469910/Updated-Phase-1-Results-of-Teclistamab-a-B-Cell?searchresult=1
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind